Flowers Foods reports this morning with a short position that has outlasted two previews, a 16% monthly price slide, and repeated analyst target cuts — and the bears have barely flinched.
Short interest has drifted fractionally lower, now at 20.6% of the free float — down roughly 3.1% on the month — but the core position is intact and the ORTEX short score has crept to 72.8, its highest reading of the past two weeks. The FINRA settlement count of 44 million shares still implies 8.6 days to cover at normal volume. Options traders, by contrast, are not adding to the pressure: the put/call ratio of 0.47 is running slightly below its 20-day average of 0.48, meaning the options market is no more defensive than usual heading into the release. The lending market remains wide open — availability at 128% means more shares are available to borrow than are already borrowed, and cost to borrow is just 0.51%. Bears face no friction in holding their positions, but no squeeze pressure either.
The debate between bulls and bears is fundamentally about whether FLO can stabilise its earnings trajectory. The bear case has been straightforward and the data has supported it: EPS estimates have been cut repeatedly, analyst targets have moved steadily lower from the $20–24 range a year ago to a consensus of $9.00 today, and the stock now trades at $7.10 — 21% below even that reduced target. EPS momentum ranks in the bottom quarter of the universe over both 30- and 90-day windows. The bull case rests on valuation: an EV/EBITDA of 7.8x and a price-to-book just above 1.2x look cheap for a branded consumer staples name, and the dividend yield — implied at around 7.3% at current prices — keeps income buyers interested. The 12-month forward EPS growth score ranks in the 70th percentile, suggesting some analysts still see a recovery path through the Dave's Killer Bread and Alpine Valley platforms, even as near-term projections have been cut.
Institutional ownership adds a layer of complexity. BlackRock reported adding over 14.6 million shares in the period ending July 31, making it the largest holder at 16.3% of shares outstanding — a substantial move into a stock that has been falling. The CFO, Diego Scaglione, made a $37,500 open-market purchase on June 8, while CEO Ryals McMullian sold $1.68 million of stock at $8.03 on April 1, before the most recent leg down. The two signals pull in opposite directions, with the CFO buy more recent and the CEO sale now looking prescient given the subsequent decline to $7.10.
The print will test whether the revenue and margin numbers offer any support for the value argument, or whether another downward revision to earnings guidance confirms that the bears' multi-month conviction position still has room to run.
See the live data behind this article on ORTEX.
Open FLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
